Multiple Sclerosis
Conditions
Keywords
Multiple Sclerosis
Brief summary
National, multicenter study: The study consists of 3 periods: 1. A baseline visit to confirm that patient is still in CIS status. All patients will be clinically evaluated for CDMS and an MRI (less than 2 months) will be analyzed to exclude MS patients according to 2010 Mc Donald's criteria. 2. Treatment period with timed evaluations 3. Post-treatment period: 4 weeks, with 2 visits following study drug discontinuation and accelerated elimination procedure. All patients who discontinue the study drug and according to investgator's decision, will perform the accelerated elimination procedure and the post- accelerated elimination visits (at 2 and 4 weeks after the end of treatment (EOT).
Interventions
DRUGTeriflunomide
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Patients enrolled in TOPIC study and extension of TOPIC study and currently treated in French extension of TOPIC study who did not convert into MS. * A baseline MRI scan (performed less than 2 months before baseline Visit ) confirming that patient is still in CIS status.
Exclusion criteria
* Contraindication for MRI, * Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease or procedure/medication making implementation of the protocol or interpretation of the study results difficult or that would put the patient at risk by participating in the study * Patients with a congenital or acquired severe immunodeficiency, a history of cancer (except for basal or squamous cell skin lesions which have been surgically excised, with no evidence of metastasis), lymphoproliferative disease, or any patient who has received lymphoid irradiation * Known history of active tuberculosis not adequately treated * Persistent significant or severe infection * History of drug or alcohol abuse * Patients must not have used Adrenocorticotrophic hormone (ACTH) or systemic corticosteroids for 2 weeks prior to inclusion * Prior use within 4 weeks before inclusion or concomitant use of cholestyramine * Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate * Prior or concomitant use of interferons, cytokine therapy, glatiramer acetate or intravenous immunoglobulins * Prior or concomitant use of natalizumab (Tysabri®) * Pregnant or breast-feeding women * Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy. * Women wishing to become pregnant during the course of the trial * Patients with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia * Human immunodeficiency virus (HIV) positive patient * Persisting elevations (confirmed by retest) of serum amylase or lipase greater than 2-fold the upper limit of normal * Known history of chronic pancreatic disease or pancreatitis * Liver function impairment or persisting elevations (confirmed by retest) of serum glutamic pyruvic transaminase (SGPT/ALT), serum glutamic oxaloacetic transaminase (SGOT/AST), or direct bilirubin greater than 1.5-fold the upper limit of normal * Known history of active hepatitis * Hypoproteinemia (e.g., in case of severe liver disease or nephrotic syndrome) with serum albumin \< 3.0 g/dL * Moderate to severe impairment of renal function, as shown by serum creatinine \> 133 μmol/L (or \> 1.5 mg/dL)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse event reporting | throughout study completion an average of 6 months | evaluation of safety and tolerability of teriflunomide 14mg per day |
| Adverse Events That Are Related to Treatment | throughout study completion an average of 6 months | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Conversion based on annualized relapse rate (ARR) | throughout study completion an average of 6 months | Conversion to clinically definite MS based on clinical evaluation and annualized relapse rate (ARR), defined as number of relapses per patient-year |
| volume of abnormal brain tissue on MRI | 3 years | — |
| Disability progression defined as a 1.0-point increase in EDSS score | confirmed after at least 12 weeks | to disability progression (12 weeks), defined as a 1.0-point increase in EDSS score (or 0.5-point increase for baseline EDSS \>5.5) confirmed after at least 12 weeks |
| Conversion based on MRI | throughout study completion an average of 6 months | Conversion to definite MS based on MRI data as defined by the demonstration of dissemination of MRI lesions in time (based on the 2010 revised McDonald criteria) within 3 years |
| Fatigue Impact Scale | throughout study completion an average of 1 year | Patient-reported fatigue based on the Fatigue Impact Scale |
| Quality of life using SF-36 | throughout study completion an average of 1 year | — |
| Proportion of disability-free subjects as assessed by the EDSS | throughout study completion an average of 1 year | Proportion of disability-free subjects as assessed by the EDSS |
| Conversion based on Clinical evaluation | throughout study completion an average of 6 months | Conversion to clinically definite MS based on clinical evaluation and annualized relapse rate (ARR), defined as number of relapses per patient-year |
Countries
France
Outcome results
None listed